In visceral and cutaneous leishmaniasis, several studies have demonstrated that the activation of macrophage PPARγ promotes disease progression, and its inhibition delays lesion development [42,43,44] (reviewed in [45]). Here, PPARG is linked to cutaneous leishmaniasis.